Taiwan health industries
A comprehensive introductory guide to Taiwan’s healthcare system and its biopharma and medical device sectors
Pharmaceuticals & life sciences publications
40 results
Loading...
Global M&A trends in health industries: 2024 mid-year outlook
M&A strategies in health industries focus on unlocking value and innovation: dealmakers gear up for a busy second half of 2024.
Global M&A trends in health industries: 2024 outlook
Competition for innovative technologies will be fierce as dealmaking headwinds begin to subside, accelerating health industries M&A in 2024.
Putting patients at the centre of quality
How can quality organisations embrace a patient-centric approach to drive value? To find out where the industry stands on ‘patient-centred quality’, we surveyed and assessed biopharmaceutical and medtech companies’ current approach to quality.
Global M&A Trends in Health Industries: 2023 Mid-Year Update
M&A will remain a key transformation tool for health and pharmaceutical companies in the second half of 2023.
GlaxoSmithKline's HR transformation journey
GlaxoSmithKline wanted to future-proof their HR function. PwC and Workday worked in collaboration to address the pain points in an employee life-cycle by optimising Workday functions and implementing ServiceNow to support HR services.
Global M&A Trends in Health Industries: 2023 Outlook
Health industries M&A is set to rebound in 2023, with investors attracted by innovation and growth prospects.
From healthcare to life care: Transforming precision health
Technology and evolving consumer preferences are setting the stage for a transformation in the way that healthcare delivers and creates personal, societal and financial value.
How to develop and commercialise digital health solutions
Our survey explores the top five challenges facing leading pharma and MedTech companies and highlights recommendations on how they can overcome these impediments.
Global M&A Industry Trends in Health Industries: 2022 Mid-Year Update
Innovation and attractive growth prospects in health industries create a strong M&A outlook for the remainder of 2022.
Taking Affiliate Quality into the future
How quality organisations must evolve to be future-ready.
Global M&A Industry Trends in Health Industries: 2022 Outlook
Heightened PE interest and investments are propelling megadeals in 2021
How to make digital health stick
The growth of digital health solutions has accelerated rapidly in the post-COVID era. But while there are plenty of innovative ideas in development, many companies are still struggling to move beyond promising pilots and into production at scale.
Sustainability in manufacturing: Delivering net-positive returns
Sustainability should not be seen as a cost that must be offset somewhere else. Manufacturers can turn sustainability into a value differentiator by focusing on three areas.
How New Zealand’s Whakarongorau Aotearoa is improving equity in healthcare
CEO Andrew Slater describes how the telehealth company has scaled up to meet unprecedented demand while staying true to its mission.
Manufacturing COO Pulse Survey
What does the future of manufacturing look like? In PwC’s COO Pulse Survey, we reveal the plans and priorities of global manufacturing executives.
Global Top Health Industry Issues 2021
In our new report, PwC’s look at four top themes that now affect global healthcare providers, insurers, pharmaceutical and life sciences companies, new entrants and employers.
Building a high-performing pharma organisation in a virtual world
Remote working is here to stay - but with some roles and activities necessitating a physical workplace, what does this mean for the pharma sector?
Empowerment will be at the heart of the new healthcare experience
COVID-19 has highlighted the importance of keeping patients, families, and caregivers informed and connected, and of valuing them as co-creators in building the future of healthcare delivery.
Pfizer’s vaccine machine
CEO Albert Bourla discusses how a company founded in the 19th century is taking on the biggest health challenges of the 21st century.
Future Pharma
New technologies and emerging trends like robotics, artificial intelligence and precision medicine are disrupting the pharmaceutical industry.
Global insights: the COVID-19 response
COVID-19 has upended healthcare around the world. As companies and governments race to produce and distribute vaccines, PwC provides insights for leaders in these challenging times.
Accelerating the health economy of tomorrow
The pandemic edits the DNA of the health system
Mission: ‘patient centricity’
How technology can help achieve personalised care for rare disease patients.
Reimagining healthcare: Telemedicine initiatives for COVID-19
Throughout history, epidemics and pandemics have driven profound changes in economic, social and business structures.
Preparing your life sciences company to go public
The number of life sciences companies raising capital through public offerings has been rising steadily for the past few years.
Social Determinants of Health
Expanding the health ecosystem to encompass where people live, work and play.
Driving the future of health
By 2030, healthcare will be centered on patients empowered to prevent diseases rather than seek treatment.
'Return on experience' in healthcare and pharmaceuticals
PwC’s 10th annual Global Consumer Insights Survey (GCIS) — which gathers the sentiments of more than 21,000 online consumers in 27 territories — shows that in addition to the traditional return on investment (ROI) metrics used to determine a healthcare or pharmaceutical company’s success, we need to introduce another...
IFRS - Issues and solutions for the pharmaceuticals and life sciences industry - 2019 edition
PwC’s insight on how to apply IFRS in common pharmaceuticals and life sciences transactions, including guidance on the new revenue standard, IFRS 15.
How Robots Will Transform the C-Suite
Senior executives need to lead a workforce that seamlessly blends human talent and automation. Visit strategy+business to read more.
New dynamics of the pharmaceutical oncology market
Amid projected growth, the pharmaceutical oncology market is undergoing significant change.
US tax reform: Implications for pharma and life sciences
US Tax Reform will impact both US and non-US Pharma companies. This PwC presentation examines some of the main provisions.
Introducing the Pharma 2020 series
PwC's Pharma 2020 series reports look into the future of the Pharmaceuticals and Life Sciences’ value chain, and they include an analysis of the strategies needed to compete successfully in the future.
Pharma 2020: Supplying the future -- Which path will you take?
PwC's report discusses how pharma companies must develop different supply chain models for different product types and patient segments, use their supply chains for market differentiation and see the role information plays to drive the flow of products and services.
Pharma 2020: Taxing times ahead
The fifth report in the series, it focusses on the opportunities and challenges from a tax perspective. It discusses how the political, economic, scientific and social trends currently shaping the commercial environment, together with the development of new, more collaborative business models, will exert increasing...
Pharma 2020: Challenging business models - Which path will you take?
Pharma 2020: Challenging business models - Which path will you take?
Pharma 2020: Marketing the future - Which path will you take?
This paper discusses how the industry is no longer being rewarded for incremental innovation, me-too products and selling the most pills. Companies need to add value to patients, and offer a package of products and health services that the market is willing to pay a premium for.
IRS Identifies Factors for Determining Deductibility of Settlement Payments
Few tax issues are more fact-intensive than determining the tax consequences to the payor of payments made under a settlement agreement with a governmental body when the agreement is silent as to the nature of the payments. In a legal advice memorandum, the IRS Office of Chief Counsel shed some light on the factors it...
Pharma 2020: Virtual R&D
Pharma 2020: Virtual R&D explores how pharma companies could dramatically improve the R&D productivity. It contents that by 2020 the R&D process may be shortened by two-thirds, success rates may dramatically increase, and clinical trial costs could be cut substantially. New computer based technologies will create a...
Loading...
Follow us
Contact us
Global Pharmaceutical and Life Sciences Assurance Leader, PwC Switzerland
Tel: +41 79 5429018
Global Health Industries Tax Leader, PwC United Kingdom
Tel: +44 (0)7793 580784